Product Details
Sublocade
Buprenorphine100 mg/0.5 mL
Solution for Injection
0.5-mL Prefilled Syringe
DIN/PIN/NPN
02483084
Manufacturer
Indivior UK Limited
Formulary Listing Date
2020-04-30
Unit Price
550.0000
Amount MOH Pays
550.0000
Coverage Status
Limited Use Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
N07BC01
Interchangeable Products
NOLU Clinical Criteria
LU Code | Auth. Period | Clinical Criteria |
---|---|---|
577 | 1 year | For the management of moderate to severe opioid use disorder as a part of a complete treatment plan that includes counselling and psychosocial support in adult patients who meet the following criteria: - The patient has been induced and is stabilized on an equivalent of 8mg to 24mg per day of transmucosal buprenorphine for a minimum of seven days; AND Recommended dose: 300mg/month for two months, followed by a maintenance dose of 100mg/month. Maintenance dose may be increased to 300mg/month only if patient does not demonstrate satisfactory clinical response. Note: In clinical trials, the 300mg/month maintenance dose did not provide additional efficacy as compared to the 100mg/month dose and was associated with a higher incidence of adverse events and study discontinuations. A minimum of 26 days is required between consecutive doses |